Despite the progressing knowledge in COVID-19 management, remdesivir is the only agent
that got approval to inhibit viral replication. However, there are limited data about effective …

Primary and secondary haemophagocytic lymphohistiocytosis (HLH) are hyperferritinaemic
hyperinflammatory syndromes with a common terminal pathway triggered by different …

Objectives Acute respiratory distress syndrome and cytokine release syndrome are the
major complications of coronavirus disease 2019 (COVID-19) associated with increased …

The emergency state caused by COVID-19 saw the use of immunomodulators despite the
absence of robust research. To date, the results of relatively few randomized controlled trials …

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged,
causing a global pandemic called COVID-19. Currently, there is no definitive treatment for …

1. Background: Literature data on bacterial infections and their impact on the mortality rates
of COVID-19 patients from Romania are scarce, while worldwide reports are contrasting. 2 …

The overproduction of proinflammatory cytokines, resulting in what has been described as a
cytokine storm or cytokine release syndrome (CRS), may be the key factor in the pathology …

Background and objective The most important presentation of COVID-19 is hyper
inflammatory condition and cytokine storm that occurs due to excessive increase of the …

The emergence of SARS-CoV-2, and the ensuing global pandemic, has resulted in an
unprecedented response to identify therapies that can limit uncontrolled inflammation …

Background Haemophagocytic lymphohistiocytosis (HLH) or macrophage activation
syndrome (MAS) has a potentially high mortality rate. Anakinra, an interleukin‐1 receptor …